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The cervical cancer epidemic continues with approximately 569,847 new cases and 311,394 
deaths reported worldwide annually [1]. Unique among human malignancies, invasive 
disease is typically diagnosed between the ages of 35 and 44 years, when young children 
are in the home and patients are in the midst of their careers. While early stage carcinomas 
(up to 2018 International Federation of Gynecology and Obstetrics [FIGO] IB1-2) can often 
be cured via radical surgery with lymphadenectomy and adjuvant therapy as indicated by 
surgico-pathologic findings, locally advanced disease (FIGO stages IB3-IVA) lends itself to 
platinum-based chemoradiation followed by high dose rate intracavitary brachytherapy [2]. 
Patients with central, isolated recurrence following definitive radiotherapy may be salvaged 
through pelvic exenteration, but in the era of chemoradiation, local recurrences are often 
accompanied by distant failure. Integration of the fully humanized monoclonal antibody, 
bevacizumab, with chemotherapy doublets to sequester vascular endothelial growth factor 
and prevent tumor angiogenesis, confers a statistically significant and clinically meaningful 
survival benefit, which is modest at best [3]. Interestingly, despite having been studied in 
many solid tumors, bevacizumab has only demonstrated a survival advantage in cervical 
cancer, 2 (of 7) trials in colorectal cancer, and in a single study of unresectable pleural 
mesothelioma. Given that prevention of the development of invasive carcinoma will always 
be preferable to treatment, there has been renewed focus on precancerous lesions (e.g., 
cervical intraepithelial neoplasia [CIN] 3) which often require invasive surgical techniques to 
eradicate (e.g., surgical excision or ablation using cryotherapy or CO2 laser).
The scientific advances in our understanding of cervical neoplasia can be traced back through 
the centuries beginning over 2000 years ago when Hippocrates the Asclepiad (460–375 
BCE) of the Greek Island of Kos originally described the disease as being so destructive “it is 
better to be left uncured than treated” [4]. The Italian cancer epidemiologist and physician 
Domenico Antonio Rigoni-Stern (1810–1855) analyzed death certificates of women in Verona 
during the period of 1760–1839 and recorded a high frequency of cervical cancer in married 
women, widows, and prostitutes; rarely did the disease manifest in virgins and nuns [5]. 
Accordingly, he postulated that the disease may arise through sexual contact. Before his 
theory would be validated, another Greek physician, Georgios Nikolaou Papanicolaou (1883–
1962) embarked on his own odyssey which brought him to Cornell University in New York 
where he developed cytologic screening for cervical cancer [6], perfecting the technique by 
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often practicing on Mrs. Andromahi Mavrogeni Papanicolaou. Following its introduction into 
clinical practice in the 1950s, the Pap smear has saved thousands of lives, further cementing 
the disease's novelty through cost-effective, non-invasive, reliable screening. Finally, from 
1976–1984, the German virologist Harald zur Hausen (1936–) identified the etiologic role 
of human papillomavirus (HPV) subtypes 16 and 18 in the development of cervical cancer 
[7], leading directly to high risk HPV DNA detection assays to augment cytologic screening 
through increased sensitivity. zur Hausen would ultimately receive the Nobel Prize in 
Physiology or Medicine in 2008 for this discovery. Not only has the identification of relevant 
viral DNA sequences allowed for the development of prophylactic HPV vaccination using 
virus-like particle technology incorporating a cDNA of the highly antigenic L1 HPV capsid 
protein, but the molecular cascade which governs virus-induced carcinogenesis has also been 
elucidated. Specifically, the HPV oncoproteins E6 and E7 degrade and inactivate the cellular 
tumor suppressor gene products, p53 and pRb, respectively, leading directly to dysregulation 
of the cell cycle [8]. Inflamed tumors develop through infection by high risk HPV subtypes 
and viral integration into host DNA which disrupts the viral regulatory E2 reading frame, 
resulting in loss of the negative feedback loop which otherwise prevents viral oncogene 
expression. With continued understanding of the immunologic tolerance taking place in the 
tumor microenvironment, we are finally in a position to consider therapeutic vaccination 
for this disease based on HPV oncogene expression. In a randomized, placebo-controlled 
phase 2 trial involving 129 women with CIN2–3 using the HPV 16 E6 and E7-based therapeutic 
vaccine, tipapkinogen sovacivec, complete resolution among vaccine-recipients with CIN3 
was 21% (compared to 0% in the placebo arm) [9].
In the September 2019 issue of the Journal of Gynecologic Oncology, Park and colleagues [10] 
have reported data from a phase 1/2a dose-escalation study of BLS-M07 to treat CIN3. The 
vaccine is novel and is orally administered five times each week (on weeks 1, 2, 4, and 8) at 
a dose of 1,000 mg. By embedding the HPV 16 E7 antigen on the surface of the Lactobacillus 
casei vaccine construct, the investigators were able to monitor disease regression using the 
Reid Colposcopic Index grading system and measure serum HPV 16 E7 antibody production. 
There were no grade 3 or 4 treatment-related adverse events or deaths observed among the 19 
patients enrolled with CIN3. Importantly, not only did vaccination induce protective humoral 
immunity, but in phase 2a, six of eight subjects (75%) were cured at 16 weeks' follow-up 
[10]. This contrasts favorably with what is observed in clinical practice during which time 
regression rates of 25% may require up to 1 year or even longer.
The oral schedule, high efficacy, absence of notable side effects, and position during the 
preinvasive course of the disease represent clear advantages of this vaccine strategy. However, 
because the trial was not placebo-controlled and the investigators performing colposcopic-
directed biopsies after vaccination may not have been blinded to the participation by 
the patients on the trial, the efficacy results will need further validation in a double-
randomized, placebo-controlled trial. In addition, in designing a confirmatory trial, a strong 
consideration for excisional biopsy (cold knife cervical conization or large loop excision of 
the transformation zone) should be made so as to pathologically confirm complete tumor 
regression induced by recipients of study vaccine. A revision of the administration schedule 
to fewer days and/or fewer weeks may have a positive impact on compliance in a real world 
setting, provided that efficacy is not compromised. Finally, applicability of this novel 
technology to patients with non-HPV 16 CIN3 along with analysis of viral DNA clearance 
through hybrid capture will also need to be addressed.
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